Z-1,1-dichloro-2,3-diphenylcyclopropanes block human prostate carcinoma cell proliferation, inhibit prostate-specific antigen expression, and initiate apoptosis

Prostate

Volumn 45, Issue 4, 2000, Pages 277-288

  Balachandran, Raghavan ^a   Grant, Stephen G ^a,b,c   Welsh, Manda J ^a   Day, Billy W ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Antimitotic agents; Cell cycle; Flow cytometry; Prostate specific antigen

Indexed keywords

1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTIMITOTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COMPLEX FORMATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TARGET CELL; TUMOR VOLUME;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR MODULATORS; GROWTH INHIBITORS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033674365     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20001201)45:4<277::AID-PROS1>3.0.CO;2-W     Document Type: Article

References (64)

1. Cancer statistics
2. The prostate: An increasing medical problem
3. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs
4. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
5. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
6. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells
7. Control of tumor progression by maintenance of apoptosis
8. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
9. Induction of apoptosis - New targets for cancer chemotherapy
10. Apoptosis induced by anticancer drugs
11. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells
12. Proliferation-dependent vs. independent programmed cell death of prostate cancer cells involves distinct gene regulation
13. Implication of cell kinetic changes during the progression of human prostatic cancer
14. Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of noble rats
15. Hormonal regulation of nuclear type II estrogen binding sites in the dorsolateral prostate of Noble rats
16. Preliminary characterization and partial purification of rat uterine nuclear type II binding sites
17. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition
18. Nuclear type II sites and malignant ceil proliferation: Inhibition by 2,6-bis-benzylidenecyclohexanones
19. Preliminary assessment of luteolin as an affinity ligand for type II estrogen-binding sites in rat uterine nuclear extracts
20. Combination therapy with a nuclear type II site agonist and 5-fluorouracil: Inhibition of mammary tumor growth
21. 3H]estradiol binding sites and prostatic cancer cell proliferation
22. 3H]estradiol binding site antagonists: Inhibition of normal and malignant prostate cell growth and proliferation
23. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
24. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer
25. Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer
26. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
27. Inhibition of prostate cancer growth by vinblastine and tamoxifen
28. Inhibition of prostate cancer growth by estramustine and colchicine
29. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc
30. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells
31. Synthesis and biological evaluation of 1,1-dichloro-2,3-diarylcyclo-propanes as antitubulin and anti-breast cancer agents
32. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast cancer cell line expressing type II estrogen-binding sites
33. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
34. Cellular targets of the antibreast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: Type II estrogen binding sites and tubulin
35. A comparison of the efficacy for antitumor activity of the nonsteroidal antiestrogens Analog II and tamoxifen in DMBA-induced rat mammary tumors
36. Effects of nonsteroidal antiestrogens, Analog II and tamoxifen, on a metastatic transplantable rat mammary tumor
37. Nonsteroidal estrogens and antiestrogens. Biological activity of cyclopropyl analogs of stilbene and stilbenediol
38. Synthesis and biological evaluation of 1,1-dichloro-2,2,3-triarylcyclopropanes as pure antiestrogens
39. Cytostatic and cytotoxic action of Z-1,1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines
40. 2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2,3-diphenylcyclopropane
41. Measurement of prostate specific antigen in serum as a screening test for prostate cancer
42. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
43. Serum prostate specific antigen as pre-screening test for prostate cancer
44. Tumor markers
45. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate specific antigen
46. Tissue specific and hormonal regulation of human prostate-specific glandular kallikrein
47. The glandular kallikrein family of enzymes: Tissue specific expression and hormonal regulation
48. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
49. The microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells - Preliminary comparisons to paclitaxel
50. Increased sensitivity of the antiestrogen-resistant MCF-7/LY2 human breast carcinoma cell line to apoptosis induced by the novel microtubule-stabilizing agent (+)-discodermolide
51. Syntheses of cyclopropyl analogs of stilbene and stilbenediol as possible antiestrogens
52. Synthesis and biological evaluation of a series of gem-dichlorocyclopropanes as antitumor agents
53. Detection of early and late stage of apoptosis with field inversion electrophoresis
54. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol®) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells
55. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells
56. Role of androgen in prostate growth and regression: Stromal-epithelial interaction
57. Androgen regulation of gene expression
58. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP
59. Down-regulation of prostate specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor binding consensus in the promoter of the PSA gene in LNCaP cells
60. Androgen-dependent growth regulation and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP
61. Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: In vivo confirmation of an androgen receptor-mediated mechanism
62. Transferrin receptor recycling in rat hepatocytes is regulated by protein phosphatase 2A, possibly through effects on microtubule-dependent transport
63. Apoptosis is accompanied by changes in bcl-2 and bax expression induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells
64. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix